Table 9.
Clinical characteristics of patients who achieved ORR after Lenvatinib and TACE treatment.
| Variables | Lenvatinib+TACE | Lenvatinib+TACE+PD-1 | P value |
|---|---|---|---|
| n=22 | n=20 | ||
| Sex (Female/Male) | 2 (9.1%)/20 (90.9%) | 5 (25.0%)/15 (75.0%) | 0.333 |
| Age, year, median (Q1,Q3) | 53 (43.0, 57.3) | 54 (48.3, 63.3) | 0.174 |
| Liver cirrhosis (No/Yes) | 8 (36.4%)/14 (63.6%) | 8 (40.0%)/12 (60.0%) | 1.000 |
| ALBI, median (Q1,Q3) | -2.7 (-2.9, -2.5) | -2.7 (-3.1, -2.6) | 0.508 |
| ALBI grade (1/2) | 14 (63.6%)/8 (36.4%) | 15 (75.0%)/5 (25.0%) | 0.644 |
| HBsAg (Negative/Positive) | 1 (4.5%)/21 (95.5%) | 4 (20.0%)/16 (80.0%) | 0.286 |
| HBV-DNA load, IU/ml (≤2000/>2000) | 15 (68.2%)/7 (31.8%) | 13 (65.0%)/7 (35.0%) | 1.000 |
| Antivirus therapy (No/Yes) | 9 (40.9%)/13 (59.1%) | 15 (75.0%)/5 (25.0%) | 0.055 |
| AFP, μg/L (≤20/>20) | 6 (27.3%)/16 (72.7%) | 6 (30.0%)/14 (70.0%) | 1.000 |
| PIVKA-II, μg/L (≤37/>37) | 4 (18.2%)/18 (81.8%) | 2 (10.0%)/18 (90.0%) | 0.753 |
| CEA, μg/L (≤10/>10) | 21 (95.5%)/1 (4.5%) | 19 (95.0%)/1 (5.0%) | 1.000 |
| CA19-9, μg/L (≤39/>39) | 16 (72.7%)/6 (27.3%) | 15 (75.0%)/5 (25.0%) | 1.000 |
| Maximun tumor size, cm, median (Q1, Q3) | 6 (3, 10.3) | 6.8 (3.4, 9.6) | 0.690 |
| Tumor number (Single/Multiple) | 9 (40.9%)/13 (59.1%) | 3 (15.0%)/17 (85.0%) | 0.130 |
| Lymph node metastasis (No/Yes) | 20 (90.9%)/2 (9.1%) | 20 (100.0%)/0 (0%) | 0.512 |
| Extrahepatic metastasis (No/Yes) | 16 (72.7%)/6 (27.3%) | 16 (80.0%)/4 (20.0%) | 0.849 |
| Macrovascular invasion (No/Yes) | 21 (95.5%)/1 (4.5%) | 13 (65.0%)/7 (35.0%) | 0.034 |
| Duration time, month, median (Q1, Q3) | 10.5 (5, 16) | 6 (4.0, 9.8) | 0.070 |
| BCLC (A/B/C) | 5 (22.7%)/9 (40.9%)/8 (36.4%) | 1 (5.0%)/8 (40.0%)/11 (55.0%) | 0.211 |
| CNLC stage (Ia-Ib/IIa-IIb/IIIa-IIIb) | 7 (31.8%)/7 (31.8%)/8 (36.4%) | 1 (5.0%)/9 (45.0%)/10 (50.0%) | 0.087 |
HCC, hepatocellular carcinoma; Q1, first quartile; Q3, third quartile; AFP, alpha-fetoprotein; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II; CA19-9, carbohydrate antigen 19-9; CEA, carcino-embryonic antigen; HBsAg, hepatitis B surface antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer staging. P<0.05 was defined as statistical significance (italicized and bold).